Tue 23 November 2021:
On Tuesday, Prince Charles will formally launch a new AstraZeneca research and development (R&D) center worth 1 billion pounds ($1.3 billion), as the company seeks to expand its medication pipeline.
AstraZeneca has distributed two billion doses of its COVID-19 vaccine, which was developed at Oxford University, and is also working on a COVID-19 preventative antibody cocktail.
However, in light of the coronavirus pandemic, the company has boosted up other areas of research while establishing a distinct division for vaccines and antibody therapy.
AstraZeneca bought Alexion, a rare-disease specialist, for $39 billion earlier this year.
“Our new Discovery Centre in Cambridge raises the bar for sustainable R&D and global collaboration across our industry,” Chief Executive Pascal Soriot said in a statement.
“It will allow us to break new boundaries in the understanding of disease biology, bring life-changing medicines to patients and power the next stage of our company’s growth.”
AstraZeneca, which has a large portfolio of treatments for diseases like cancer, heart disease and diabetes, said the center would support research into specialized medicines and next-generation therapeutics, including gene-editing and cell therapies.
Prince Charles, the heir to the throne and son of Queen Elizabeth, will take a walking tour of the facility and deliver a brief address during the launch.
_____________________________________________________________________________
FOLLOW INDEPENDENT PRESS:
TWITTER (CLICK HERE)
https://twitter.com/IpIndependent
FACEBOOK (CLICK HERE)
https://web.facebook.com/ipindependent
Think your friends would be interested? Share this story!
